Literature DB >> 12733471

Improving communication of drug risks to prevent patient injury: proceedings of a workshop.

William H Campbell1, Robert M Califf.   

Abstract

PURPOSE: The Centers for Education & Research on Therapeutics (CERTs) is conducting a series of workshops on managing the risks of therapeutics, with the ultimate goal to develop an agenda for research and education about risk and its management. This paper presents the results of the first workshop in the series, a 2-day meeting focused on communication of drug risks to healthcare professionals and patients.
METHODS: The 50 workshop participants represented the medical-products industry, academia, consumer groups, regulatory bodies and the media. Together, they sought to identify and understand barriers to successful risk communication, to identify tools or methods that could improve risk communication, and to develop research and education agendas that would lead to better risk communication in the future.
RESULTS: Limitations of current methods of risk communication were identified, and research and education agendas were proposed to clarify and resolve these issues.
CONCLUSION: Common themes for potential solutions include enhanced education of healthcare providers, increased motivation of patients and families, use of creative communication technologies, and better organization of and access to medical records and information.

Entities:  

Mesh:

Year:  2003        PMID: 12733471     DOI: 10.1002/pds.761

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  5 in total

Review 1.  Managing the interface with marketing to improve delivery of pharmacovigilance within the pharmaceutical industry.

Authors:  Brian Edwards
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

2.  Public pharmacovigilance communication: a process calling for evidence-based, objective-driven strategies.

Authors:  Priya Bahri
Journal:  Drug Saf       Date:  2010-12-01       Impact factor: 5.606

3.  An industry perspective on the Erice declaration and risk minimisation plans.

Authors:  Simon Ingate; Deborah Tranter; Anjan Banerjee; Andrew Hobbs
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

4.  Effectiveness of safety warnings in atypical antipsychotic drugs: an interrupted time-series analysis in Spain.

Authors:  Gabriel Sanfélix-Gimeno; Pedro Cervera-Casino; Salvador Peiró; Beatriz González López-Valcarcel; Amparo Blázquez; Teresa Barbera
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

5.  Risk Communication and the Pharmaceutical Industry: what is the reality?

Authors:  Brian Edwards; Sweta Chakraborty
Journal:  Drug Saf       Date:  2012-11-01       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.